Clinical Trials
12
Active:0
Completed:4
Trial Phases
3 Phases
Phase 1:4
Phase 2:5
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (41.7%)Phase 1
4 (33.3%)Phase 3
3 (25.0%)Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 2
Recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Drug: MY008211A tablets
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT06933914
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology, Chinese Academy of Medical Sciences), Tianjin, Tianjin, China
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
Phase 3
Recruiting
- Conditions
- Paroxysmal Nocturnal Haemoglobinuria (PNH)
- Interventions
- Drug: MY008211A tablets
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 66
- Registration Number
- NCT06932744
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Chinese Academy of Medical Sciences Hematology Hospital, Tianjin, Tianjin, China
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Phase 3
Recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: MY008211A tablets
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06932471
- Locations
- 🇨🇳
Peking Union Medical College Hospital (PUMCH)., Beijing, Beijing, China
QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study
Phase 2
Completed
- Conditions
- Cough
- Interventions
- Drug: QR052107B 100 mgDrug: QR052107B 400 mgDrug: Placebo
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 270
- Registration Number
- NCT06920836
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
Phase 3
Not yet recruiting
- Conditions
- Essential Hypertension
- Interventions
- Drug: QR12000 75mgDrug: QR12000 75mg placeboDrug: QR12000 150mg placeboDrug: QR12000 150mg
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 810
- Registration Number
- NCT06716970
- Prev
- 1
- 2
- 3
- Next
News
No news found